Literature DB >> 17192618

Engineered site-directed labeling of nicotinic acetylcholine receptors using reactive epibatidine derivatives: appraisal of epibatidine-docking models in neuronal and muscular receptors.

Elias Sakr1, Florence Kotzyba-Hibert, Joerg Grande, Rund Hovius, Horst Vogel, Sonia Bertrand, Daniel Bertrand, Maurice Goeldner.   

Abstract

We developed an engineered site-directed labeling method (Foucaud et al., 2001) to investigate ligand receptor interactions on the acetylcholine (ACh)- binding site of nicotinic acetylcholine receptors (nAChRs). The method uses cysteine receptor mutants, together with cysteine-reactive ligand analogs, to generate a site-directed covalent reaction within the binding site. We selected epibatidine (EPB) as a prototypical ligand, acting at all types of nAChRs with sufficient affinity to allow this study. Accordingly, we synthesized three cysteine-reactive derivatives, all modified at the C-3 of the pyridine ring of the alkaloid with NCS; -NHCOCH2Cl, and -CH2Cl groups, respectively (Fig. 1). The binding properties have been established on rat brain, alpha7-5HT3 chimera, and Torpedo membranes, respectively, whereas the functional properties were tested on alpha4beta2 and alpha7 receptor expressed in oocytes and Cys-less muscular receptor expressed in HEK cells (Sakr et al., 2005).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192618     DOI: 10.1385/JMN:30:1:35

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  2 in total

1.  Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites.

Authors:  Nicolas Le Novère; Thomas Grutter; Jean-Pierre Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

2.  Cysteine mutants as chemical sensors for ligand-receptor interactions.

Authors:  B Foucaud; P Perret; T Grutter; M Goeldner
Journal:  Trends Pharmacol Sci       Date:  2001-04       Impact factor: 14.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.